A study that looks at Accelerated Radiation Therapy (ART) on the breast VS on the breast and lymph nodes
New York Presbyterian Hospital - Queens, Weill Cornell Medical College, Brooklyn Methodist Hospital - NewYork Presbyterian
Trial Summary
This study is comparing two different approaches for treating low-risk Ductal Carcinoma in Situ (DCIS), a type of non-invasive breast cancer. One approach that the study is trying to evaluate is active monitoring (AM), which involves the regular monitoring of cancer to see if it changes or grows, but not remove it immediately. Then, the study compares AM to the approach of surgery, which involves removing the cancerous cells. By doing so, the study aims to determine if active monitoring is as effective as surgery in treating non-intrusive breast cancer patients, without negatively impacting cancer outcomes or quality of life.
Trial Design
74 breast cancer patients with varying sizes of tumors will be divided into two groups: Group 1 will receive ART to the breast or chest wall with a concomitant boost to the original tumor bed, while Group 2 will receive ART to the breast, chest wall, and lymph nodes, including the original tumor bed. The treatment is completed in three weeks with 15 fractions, and patients are followed up regularly for five years after the completion of treatment.
Inclusion Criteria
1. Are over 18 years old
2. Are pre- or post- menopausal
3. Are woman
4. Have breast cancer (Stage I-III)
Exclusion Criteria
1. Have received previous radiation therapy to a certain breast or nodal area
2. Are pregnant or lactating
3. Are receiving chemotherapy (exceptions apply)
Exclusion criteria are conditions or characteristics if they apply to you, may likely make you ineligible to participate in the study.
Inclusion criteria is a checklist of items, if they apply to you, may make you eligible to be included for the study.